指南与共识肥胖与代谢综合征糖尿病

EASL-EASD-EASO临床实践指南在重度肥胖人群非酒精性脂肪性肝病管理中的应用:是否导致过度转诊?

EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?
指南 / 共识 · Diabetologia · 2017-03-28

本研究为单中心回顾性观察研究,纳入2014年11月1日至2015年12月31日转诊至内分泌、糖尿病与营养科的385例重度肥胖(BMI≥35 kg/m2)患者,回顾性应用EASL-EASD-EASO非酒精性脂肪性肝病管理指南。结果显示,使用NAFLD纤维化评分(NFS)可使75.1%(289例)患者被转诊至专科,而NFS联合瞬时弹性成像(TE)可将28例(25%)从中/高风险组重新分类为低风险,并使67.7%(261例)患者被转诊。作者认为这一比例相对于重度肥胖人群晚期纤维化(约10%)和非酒精性脂肪性肝炎(NASH,约30%)的预期患病率而言过高。

要点

  • 在385例重度肥胖患者中,NAFLD患病率为81.3%(313例)。
  • 单用NFS应用指南可使75.1%(289例)患者被转诊至专科。
  • NFS联合TE可将28例(25%)从中/高风险组重分类为低风险,转诊比例为67.7%(261例)。

核心结论

  • 回顾性应用EASL-EASD-EASO指南于本科室常规临床实践的代表性队列,会导致过多数量的专科转诊,并导致不合理的医疗费用增加。
  • 亟需针对病态肥胖个体筛查NASH和晚期纤维化的生物标志物及特定策略,以帮助改进现有指南。

研究设计与样本

  • 单中心回顾性观察研究,纳入2014年11月1日至2015年12月31日转诊至内分泌、糖尿病与营养科的重度肥胖(BMI≥35 kg/m2)患者385例。
  • 回顾性应用EASL-EASD-EASO非酒精性脂肪性肝病管理指南,依次使用NAFLD纤维化评分(NFS),以及在部分个体中联合NFS与瞬时弹性成像(TE)测量。

主要发现

  • 队列中识别出313例(81.3%)NAFLD患者。
  • 使用NFS应用EASL-EASD-EASO指南可导致高达289例(75.1%)患者被转诊至专科。
  • NFS联合TE测量将28例(25%)个体从中/高风险组重新分类为低风险,并导致261例(67.7%)患者被转诊至专科。
  • 作者指出这些比例相对于重度肥胖人群中晚期纤维化约10%和NASH约30%的预期患病率而言显得过高。

临床怎么用

  • 作者认为,在重度肥胖个体中回顾性应用现行EASL-EASD-EASO指南会导致过多专科转诊和不合理的医疗费用增加。
  • 作者提出,亟需针对病态肥胖个体筛查NASH和晚期纤维化的生物标志物及特定策略,以改进现有指南。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: We aimed to assess the application of the recent European Association for the Study of the Liver (EASL)-European Association for the Study of Diabetes (EASD)-European Association for the Study of Obesity (EASO) clinical practice guidelines for the management of non-alcoholic fatty liver disease (NAFLD) in severely obese individuals in routine clinical practice. METHODS: We performed a single-centre retrospective observational study of 385 patients referred for severe obesity (BMI ≥ 35 kg/m2) to our Endocrinology, Diabetes and Nutrition department, between 1 November 2014 and 31 December 2015. The recent EASL-EASD-EASO clinical practice guidelines for the management of NAFLD were retrospectively applied to the cohort using, successively, the NAFLD fibrosis score (NFS) and a combination of the NFS and transient elastography (TE) measurement in a subgroup of individuals. RESULTS: We identified 313 (81.3%) individuals with NAFLD in the cohort. The application of the EASL-EASD-EASO guidelines using NFS would lead to referral to a specialist for up to 289 individuals (75.1%) in the cohort. The combination of NFS and TE measurement reclassified 28 (25%) individuals from the medium/high risk group to low risk and would lead to the referral of 261 (67.7%) individuals to a specialist. These proportions appear to be excessive given the expected prevalence of advanced fibrosis and non-alcoholic steatohepatitis (NASH) of around 10% and 30%, respectively, in the severely obese population. CONCLUSIONS/INTERPRETATION: This is the first study to assess the strategy proposed by the EASL-EASD-EASO clinical practice guidelines for the management of NAFLD in severely obese individuals. The retrospective application of the guidelines in a cohort representing the routine clinical practice in our department would lead to an excessive number of specialist referrals and would also lead to an unjustified increase in health costs. Biomarkers and specific strategy for the screening of NASH and advanced fibrosis in morbidly obese individuals are thus crucially needed and would help to improve the actual guidelines.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Blond E, Disse E, Cuerq C, et al. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral? Diabetologia. 2017. PMID: 28352941. doi:10.1007/s00125-017-4264-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。